Cocktail treatment with EGFR-specific and CD133-specific chimeric antigen receptor-modified T cells in a patient with advanced cholangiocarcinoma

Toxicities of chimeric antigen receptor T cells: recognition and management

(2016) Jennifer N. Brudno et al.   BLOOD

Making Better Chimeric Antigen Receptors for Adoptive T-cell Therapy

(2016) M. V. Maus et al.   CLINICAL CANCER RESEARCH

CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients

(2016) Cameron J. Turtle et al.   JOURNAL OF CLINICAL INVESTIGATION

Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy

(2016) Hanren Dai et al.   JNCI-Journal of the National Cancer Institute

Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach?

(2016) Michael B. Bernstein et al.   Nature Reviews Clinical Oncology

Chimeric antigen receptor-modified T cells for the treatment of solid tumors: Defining the challenges and next steps

(2016) Gregory L. Beatty et al.   PHARMACOLOGY & THERAPEUTICS

Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed/refractory non-small cell lung cancer

(2016) Kaichao Feng et al.   Science China-Life Sciences

CD133, Selectively Targeting the Root of Cancer

(2016) Jörg Schmohl et al.   Toxins

Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy

(2016) Hanren Dai et al.   JNCI-Journal of the National Cancer Institute

Immune-priming of the Tumor Microenvironment by Radiotherapy

(2015) Vafa Shahabi et al.   AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

Epidemiology of cholangiocarcinoma

(2015) Annika Bergquist et al.   BEST PRACTICE & RESEARCH IN CLINICAL GASTROENTEROLOGY

Tuning Sensitivity of CAR to EGFR Density Limits Recognition of Normal Tissue While Maintaining Potent Antitumor Activity

(2015) H. G. Caruso et al.   CANCER RESEARCH

Targeted Therapy in Biliary Tract Cancers

(2015) Amartej Merla et al.   CURRENT TREATMENT OPTIONS IN ONCOLOGY

Recent advances for the treatment of pancreatic and biliary tract cancer after first-line treatment failure

(2015) Concetta Elisa Onesti et al.   Expert Review of Anticancer Therapy

Tumor Microenvironment Versus Cancer Stem Cells in Cholangiocarcinoma: Synergistic Effects?

(2015) Maurizio Romano et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial

(2015) Encouse B Golden et al.   LANCET ONCOLOGY

Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia

(2015) David L. Porter et al.   Science Translational Medicine

Tolerance and efficacy of autologous or donor-derived T cells expressing CD19 chimeric antigen receptors in adult B-ALL with extramedullary leukemia

(2015) Hanren Dai et al.   OncoImmunology

Immune Escape Mechanisms as a Guide for Cancer Immunotherapy

(2014) G. L. Beatty et al.   CLINICAL CANCER RESEARCH

Multifactorial T-cell Hypofunction That Is Reversible Can Limit the Efficacy of Chimeric Antigen Receptor-Transduced Human T cells in Solid Tumors

(2014) E. K. Moon et al.   CLINICAL CANCER RESEARCH

Cholangiocarcinoma

(2014) Nataliya Razumilava et al.   LANCET

Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial

(2014) David Malka et al.   LANCET ONCOLOGY

Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia

(2014) M. L. Davila et al.   Science Translational Medicine

Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation

(2013) J. N. Kochenderfer et al.   BLOOD

Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia

(2013) Stephan A. Grupp et al.   NEW ENGLAND JOURNAL OF MEDICINE

Identification of a Titin-Derived HLA-A1-Presented Peptide as a Cross-Reactive Target for Engineered MAGE A3-Directed T Cells

(2013) B. J. Cameron et al.   Science Translational Medicine

CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia

(2013) R. J. Brentjens et al.   Science Translational Medicine

Blockade of PD-1 immunosuppression boosts CAR T-cell therapy

(2013) Liza B John et al.   OncoImmunology

Recent advances in cancer stem cell research for cholangiocarcinoma

(2012) Toshio Kokuryo et al.   Journal of Hepato-Biliary-Pancreatic Sciences

Prognostic impact of cancer stem cell-related markers in non-small cell lung cancer patients treated with induction chemoradiotherapy

(2012) Kazuhiko Shien et al.   LUNG CANCER

Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma

(2012) Michael A. Postow et al.   NEW ENGLAND JOURNAL OF MEDICINE

Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma

(2011) C. U. Louis et al.   BLOOD

Molecular Pathways: Hypoxia Response in Immune Cells Fighting or Promoting Cancer

(2011) Asis Palazón et al.   CLINICAL CANCER RESEARCH

Strong expression of CD133 is associated with increased cholangiocarcinoma progression

(2011) Kawin Leelawat   WORLD JOURNAL OF GASTROENTEROLOGY

Lentiviral vector mediated modification of mesenchymal stem cells & enhanced survival in an in vitro model of ischaemia

(2011) Lisa McGinley et al.   Stem Cell Research & Therapy